BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28637622)

  • 1. Familial CEBPA-mutated acute myeloid leukemia.
    Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
    Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and management of germline CEBPA-mutated carriers.
    Pan L; Li Y; Gao H; Lai X; Cai Y; Chen Z; Li X; Wang SY
    Leuk Res; 2024 Mar; 138():107453. PubMed ID: 38442594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
    Zhang JP; Lin D; Wang SC; Li Y; Chen YM; Wang Y; Wei H; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1008-1012. PubMed ID: 33445848
    [No Abstract]   [Full Text] [Related]  

  • 4. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
    Yuan J; He R; Alkhateeb HB
    Curr Hematol Malig Rep; 2023 Oct; 18(5):121-129. PubMed ID: 37261703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants.
    Harrigan AM; Trottier AM
    Fam Cancer; 2023 Jul; 22(3):331-339. PubMed ID: 36879149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia due to germline CEBPA mutation in a Syrian family.
    Wafa A; Ali B; Moassass F; Kheder M; Aljapawe A; Al-Halabi B; Mrasek K; Liehr T; Al-Achkar W
    Mol Genet Genomic Med; 2022 Feb; 10(2):e1854. PubMed ID: 35032366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
    Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
    Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
    Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
    [No Abstract]   [Full Text] [Related]  

  • 10. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
    Wilhelmson AS; Porse BT
    Br J Haematol; 2020 Aug; 190(4):495-507. PubMed ID: 32086816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
    Ahn SY; Kim T; Kim M; Song GY; Jung SH; Yang DH; Lee JJ; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim HJ; Ahn JS; Kim DDH
    Cancer Res Treat; 2023 Jul; 55(3):1011-1022. PubMed ID: 36701843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
    Wang B; Wen L; Wang Z; Chen S; Qiu H
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
    Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
    Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.
    Pathak A; Seipel K; Pemov A; Dewan R; Brown C; Ravichandran S; Luke BT; Malasky M; Suman S; Yeager M; ; ; Gatti RA; Caporaso NE; Mulvihill JJ; Goldin LR; Pabst T; McMaster ML; Stewart DR
    Haematologica; 2016 Jul; 101(7):846-52. PubMed ID: 26721895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline CEBPA mutation in familial acute myeloid leukemia.
    Boada M; Catalán AI; Ottati C; Bentancour F; Lens D; Guillermo C; Grille S
    Hematol Rep; 2021 Sep; 13(3):9114. PubMed ID: 34733449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical characteristics and prognosis of cytogenetically normal AML with single mutations of CEBPA.
    Kang Y; Chen X; Fang F; Zhang L; Wang J; Tian C; Guo W; Xu J; Ren H; Muyey DM; Tan Y; Xu Z; Wang H
    Int J Lab Hematol; 2021 Dec; 43(6):1424-1431. PubMed ID: 34216417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of acute myeloid leukemia with unusual germline
    Mendoza H; Chen PH; Pine AB; Siddon AJ; Bale AE; Gowda L; Killie A; Richards J; Varin-Tremblay C; Kloss R; Podoltsev NA
    Leuk Lymphoma; 2021 May; 62(5):1251-1254. PubMed ID: 33345654
    [No Abstract]   [Full Text] [Related]  

  • 18. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
    Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
    Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
    Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
    Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.